KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovoCure (NVCR) Invested Capital (2016 - 2026)

NovoCure's Invested Capital history spans 13 years, with the latest figure at $330.7 million for Q1 2026.

  • On a quarterly basis, Invested Capital fell 8.63% to $330.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $330.7 million, a 8.63% decrease, with the full-year FY2025 number at $340.5 million, down 5.47% from a year prior.
  • Invested Capital hit $330.7 million in Q1 2026 for NovoCure, down from $340.5 million in the prior quarter.
  • Over the last five years, Invested Capital for NVCR hit a ceiling of $1.0 billion in Q3 2022 and a floor of $330.7 million in Q1 2026.
  • Historically, Invested Capital has averaged $650.8 million across 5 years, with a median of $415.7 million in 2023.
  • Biggest five-year swings in Invested Capital: increased 7.21% in 2022 and later plummeted 62.48% in 2024.
  • Tracing NVCR's Invested Capital over 5 years: stood at $1.0 billion in 2022, then dropped by 7.49% to $931.3 million in 2023, then plummeted by 61.33% to $360.2 million in 2024, then dropped by 5.47% to $340.5 million in 2025, then fell by 2.86% to $330.7 million in 2026.
  • Business Quant data shows Invested Capital for NVCR at $330.7 million in Q1 2026, $340.5 million in Q4 2025, and $341.3 million in Q3 2025.